Key result
Mitral valve repair for ischemic mitral regurgitation had lower unadjusted hospital mortality than replacement (5% vs 13%, p=0.01), but was not an independent predictor of mortality after adjustment.
Why the study?
The benefit of mitral valve repair over replacement in patients with ischemic mitral regurgitation remains controversial.
Does mitral valve repair improve hospital mortality compared to replacement in patients with ischemic mitral regurgitation?
Cohort (n=393)
Does mitral valve repair improve hospital mortality compared to replacement in patients with ischemic mitral regurgitation?
Absolute Event Rate: 5% vs 13%
p-value: p=0.01
In patients with ischemic mitral regurgitation, mitral valve repair does not offer an early survival benefit over replacement after adjusting for baseline differences such as age, urgency, and left ventricular function.
Adjusted analysis shows no independent mortality benefit for repair; leaves open need for randomized trials in ischemic mitral regurgitation.
BACKGROUND: The benefit of mitral valve repair over replacement in patients with ischemic mitral regurgitation is still controversial. We report our early postoperative outcomes of repair versus replacement. METHODS: Data were collected for patients undergoing first-time mitral valve surgery for ischemic mitral regurgitation between 1990 and 2009 (n = 393). Patients who underwent combined procedures for papillary muscle rupture, post-infarction ventricular septal defect, endocarditis, or any previous cardiac surgery were excluded. Preoperative demographics, operative variables, and hospital outcomes were analyzed, and multivariable regression analysis was employed to identify independent predictors of hospital mortality. RESULTS: Valve repair was performed in 42% (n=164) of patients and replacement in 58% (n=229). Patients who underwent replacement were older and had a higher prevalence of unstable angina, New York Heart Association class IV symptoms, preoperative cardiogenic shock, preoperative myocardial infarction, peripheral vascular disease, renal failure, and urgent or emergency surgery (all p < 0.05). Unadjusted hospital mortality was higher in patients undergoing valve replacement (13% versus 5%, p = 0.01). Valve repair was associated with a lower prevalence of postoperative low cardiac output syndrome. Multivariable analysis revealed that age, urgency of operation, and preoperative left ventricular function were independent predictors of hospital mortality. Importantly, mitral valve repair versus replacement was not an independent predictor of hospital mortality. CONCLUSION: Our data did not suggest an early survival benefit to mitral valve repair over replacement for ischemic mitral regurgitation. However, age, left ventricular dysfunction, and the need for urgent surgery were independently associated with hospital mortality.
No takes yet. Share an insight, caveat, or question.
Elhenawy et al. (2020) conducted a cohort in Ischemic mitral regurgitation (n=393). Mitral valve repair vs. Mitral valve replacement was evaluated on Hospital mortality (p=0.01). Mitral valve repair for ischemic mitral regurgitation had lower unadjusted hospital mortality than replacement (5% vs 13%, p=0.01), but was not an independent predictor of mortality after adjustment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: